Overview

Carisma Therapeutics is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

07 Mar '23
Carisma Therapeutics Closes Merger with Sesen Bio
Shares of Carisma to commence trading on Nasdaq under new ticker symbol "CARM" on March 8, 2023 Resulting cash position of approximately $140 million provides runway through 2024; expected to enable multiple clinical readouts across Carisma programs PHILADELPHIA, March 7, 2023 /PRNewswire/ -- 

Recent Events

Corporate Presentation

Corporate Governance

Steven Kelly

Steven Kelly

President and Chief Executive Officer, Director

Steven Kelly

President and Chief Executive Officer, Director

Steven Kelly has served as Carisma’s President and Chief Executive Officer and as a member of the Carisma board of directors since February 2018. Prior to joining Carisma, Mr. Kelly served as Chief Executive Officer of Pinteon Therapeutics, a biotechnology company, from April 2014 to July 2015 and
Read More
Image of Richard Morris

Richard Morris

Chief Financial Officer

Richard Morris

Chief Financial Officer

Richard Morris has served as Carisma’s Chief Financial Officer since June 2021. Prior to joining Carisma, Mr. Morris served as Chief Financial Officer of Passage Bio, Inc., a genetic medicines company, from October 2019 to May 2021 and as Executive Vice President and Chief Financial Officer of
Read More
Image of Michael Klichinsky, Pharm.D., Ph.D.

Michael Klichinsky Pharm.D., Ph.D.

Chief Scientific Officer

Michael Klichinsky Pharm.D., Ph.D.

Chief Scientific Officer

Michael Klichinsky, Pharm.D., Ph.D. has served as Carisma’s Chief Scientific Officer since April 2022. He co-founded Carisma in 2016 and served as Vice President of Discovery of Carisma from October 2018 to April 2021 and as Senior Vice President of Research of Carisma from April 2021 to April
Read More
Image of Daniel Cushing

Daniel Cushing PhD

Chief Technology & Development Officer

Daniel Cushing PhD

Chief Technology & Development Officer

Dan is responsible for product development at Carisma Therapeutics. He has over 25 years of pharmaceutical and biotechnology industry experience, including discovery research, drug development, medical affairs, and regulatory affairs. Over his career, Dan has led the development and registration of
Read More
Image of Tom Wilton

Tom Wilton

Chief Business Officer

Tom Wilton

Chief Business Officer

Tom joined Carisma Therapeutics in September 2019. He brings over 20 years of pharmaceutical and biotechnology industry experience, including corporate strategy, business development, R&D operations and marketing. Tom most recently served as the Chief Business Officer for LogicBio Therapeutics,
Read More